No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
06628 TRANSCENTA-B
- 1.710
- -0.040-2.29%
Trading Apr 26 13:06 CST
746.20MMarket Cap-1461P/E (TTM)
1.740High1.700Low44.50KVolume1.700Open1.750Pre Close77.07KTurnover0.01%Turnover RatioLossP/E (Static)436.38MShares6.20052wk High0.66P/B746.20MFloat Cap1.17052wk Low--Dividend TTM436.38MShs Float16.180Historical High--Dividend LFY2.29%Amplitude1.170Historical Low1.731Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Chuangsheng Group-B (06628.HK) spent HK$70,500 to buy back 40,500 shares on April 25
Gelonghui April 25 | Chuangsheng Group-B (06628.HK) announced that it spent HK$70,500 to repurchase 40,500 shares on April 25.
Chuangsheng Group-B (06628) bought back 500 shares on April 24
Chuangsheng Group-B (06628) announced that on April 24, 2024, the company spent HK$835 to repurchase...
Chuangsheng Group-B (06628) spent about HK$69,300 to buy back 42,500 shares on April 23
Chuangsheng Group-B (06628) issued an announcement to repurchase approximately HK$69,300 on April 23, 2024...
Chuangsheng Group-B (06628) spent HK$4,680 to buy back 3,000 shares on April 22
According to the Zhitong Finance App, Chuangsheng Group-B (06628) announced that it will spend HK$4,680 to repurchase 3,000 shares on April 22, 2024.
Chuangsheng Group-B (06628) repurchased 3,500 shares on April 18
Chuangsheng Group-B (06628) announced that the company spent 5099.85 on April 18, 2024...
創勝集團-B：2023年年度報告
Comments
high success rate
$TRANSCENTA-B(06628.HK$ backed by Lilly and Temasek, high success rate for Claudin 18.3
$TRANSCENTA-B(06628.HK$ On October 9, the CDE website showed that The application for clinical trial of MBOS TST005 injection was accepted by the Food and Drug Administration, and the indication is solid tumor. TST005 is the second bi-functional anti-PD-L1 and TGF-β trap fusion protein to initiate a global clinical study.
3
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg